EHA 2019 European Hematology Association -  June 13-16,  2019
Chronic Myeloid Leukemia - CML - 24th Congress of EHA
​Amsterdam, Netherlands 



Abstract Book


SOME INTERESTING ABSTRACTS FOR CML


R-INTERFERON TREATMENT BEFORE TKI START IMPROVES TREATMENT FREE REMISSION RATE (TFR) PARTICULARLY IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WITH THE LESS FAVORABLE E13A2 BCR-ABL1 TRANSCRIPT TYPE
​          
IN SEARCH OF THE RESIDUAL LEUKAEMIC CLONE IN CHRONIC MYELOID LEUKAEMIA PATIENTS IN TREATMENT-FREE REMISSION

DDPCR AT THE TIME OF TKI DISCONTINUATION IN CHRONIC PHASE CHRONIC MYELOID PATIENTS IS PREDICTIVE OF TREATMENT-FREE REMISSION OUTCOME
 
PROGNOSTIC FACTORS FOR MOLECULAR RELAPSE-FREE SURVIVAL AFTER DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA BASED ON RUSSIAN MULTICENTER PROSPECTIVE TRIAL (RU-SKI)
 
FACTORS INFLUENCING PATIENT PREFERENCES FOR DISCONTINUATION OF TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA

​CORRELATION BETWEEN LEVELS OF EARLY MOLECULAR RESPONSE AND BCR-ABL TRANSCRIPT TYPE IN STABLE DMR ATTAINMENT IN CML PATIENTS TREATED WITH IMATINIB

SAFETY OF IMATINIB AND ITS GENERICS IN CHRONIC MYELOID LEUKEMIA: A SUBANALYSIS OF POLISH IMATINIB GENERICS REGISTRY AFTER THREE YEARS OF OBSERVATION
  ​​
DOUBLING TIME AFTER FIRST ATTEMPT OF IMATINIB DISCONTINUATION IS HELPFUL TO IDENTIFY THE BEST CANDIDATE FOR THE SECOND ATTEMPT FOR TREATMENT-FREE REMISSION WITH DASATINIB: CANADIAN TRAD TRIAL
 
FOLLOW-UP OF LOWER DOSE DASATINIB 50MG DAILY AS FRONTLINE THERAPY IN NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP)
 
DASFREE 2-YEAR UPDATE: DASATINIB DISCONTINUATION IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND DEEP MOLECULAR RESPONSE (DMR)

DOSING PATTERNS OF DASATINIB AND NILOTINIB USE IN SIMPLICITY, AN OBSERVATIONAL STUDY IN CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS (PTS) IN ROUTINE CLINICAL PRACTICE

AGE ≥59 YEARS IS ASSOCIATED WITH A HIGHER PROBABILITY OF CARDIOVASCULAR EVENTS IN PATIENTS RECEIVING NILOTINIB FOR CML: A SINGLE CENTRE RETROSPECTIVE ANALYSIS
 
COMBINATION OF ASCIMINIB PLUS NILOTINIB (NIL) OR DASATINIB (DAS) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA (CML): RESULTS FROM A PHASE 1 STUDY     

PRIMARY RESULTS OF THE PHASE 4 BYOND STUDY OF BOSUTINIB FOR PRETREATED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
​
​EFFICACY AND SAFETY FOLLOWING DOSE REDUCTION OF BOSUTINIB IN PREVIOUSLY TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA: ANALYSIS OF THE PHASE 4 BYOND TRIAL

PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY

PLANNED PREGNANCY IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA RECEIVING TYROSINE KINASE INHIBITOR THERAPY
​ 
OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY

PRIMARY THERAPY AND RELATIVE SURVIVAL AMONG ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA: A POPULATION-BASED STUDY IN THE NETHERLANDS, 1989-2016.
 
ANALYSIS OF THE INFLUENCE OF AGE ON MAJOR MOLECULAR RESPONSE,DEEP MOLECULAR RESPONSE AND SURVIVAL OUTCOMES IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS (TKIS)

INFLUX/EFFLUX TRANSPORTERS IN CHRONIC MYELOID LEUKEMIA: THE INFLUENCE OF GENETIC VARIANTS ON SUSCEPTIBILITY AND DRUG RESPONSE
 
THE POTENTIAL IMPACT OF SWITCH TO SECOND GENERATION TYROSINE KINASE INHIBITORS IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE WHO HAD NO OPTIMAL RESPONSE TO 3 MONTHS OF INITIAL IMATINIB THERAPY
 
AN UPDATED META-ANALYSIS OF THE RISKS OF ARTERIAL AND VENOUS OCCLUSIVE EVENTS WITH NEW GENERATION BCR-ABL TKIS IN PATIENTS WITH CHRONIC MYELOID LEUKAEMIA
 
CHARACTERISTICS AND OUTCOMES OF THE TREATMENT PATIENTS WITH T315I MUTATION CML

DASATINIB ATTENUATES THROMBIN GENERATION AND CLOT RETRACTION OF CONVULXIN ACTIVATED HUMAN PLATELETS
 
GENE EXPRESSION PROFILING OF CD26+ LEUKEMIC STEM CELL POPULATION FROM CML PATIENTS

INDIVIDUAL RESPONSE OF CML PATIENTS TO TKI DOSE REDUCTION CAN RELIABLY IDENTIFY PATIENTS WITH HIGH RISK OF MOLECULAR RELAPSE AFTER TREATMENT CESSATION
 
ANTI-LEUKEMIA EFFECT OF DISULFIRAM AND ASCORBATE IN ABL TYROSINE KINASE INHIBITOR RESISTANT LEUKEMIA CELLS

DNA-BASED BCR-ABL1 ANALYSIS PROVIDES A “TRAFFIC LIGHT” STRATIFICATION MODEL FOR CHRONIC MYELOID LEUKEMIA WITH IMPLICATIONS FOR TREATMENT FREE REMISSION
 
IDENTIFICATION OF PROTEIN-PROTEIN INTERACTIONS NECESSARY FOR MAINTENANCE OF BCR-ABL CORE COMPLEX
 
QUALITY OF LIFE IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH DEEP MOLECULAR RESPONSE AFTER STOPPING TREATMENT BY TYROSINE KINASE INHIBITORS AT LONG-TERM FOLLOW-UP
 
DETECTION OF COMPLEX VARIANT T(9;22) CHROMOSOME TRANSLOCATIONS IN NEWLY DIAGNOSED CASES OF CHRONIC MYELOID LEUKAEMIA
 
PERSPECTIVE OF THE PATIENT WITH CML AND FAILURE TO TREATMENT WITH IMATINIB AT AN ENVIROMENT OF LIMITED RESOURCES
 
​
​       RETURN to   Congresses, conferences, meetings, ….. on  chronic myeloid leukemia